These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33515702)

  • 1. Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis.
    Pellegrini L; Novak U; Andres M; Suter T; Nagler M
    Crit Rev Oncol Hematol; 2021 Mar; 159():103238. PubMed ID: 33515702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials.
    Yun S; Vincelette ND; Acharya U; Abraham I
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):31-37.e13. PubMed ID: 27780690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
    Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
    PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
    Boriani G; Corradini P; Cuneo A; Falanga A; Foà R; Gaidano G; Ghia PP; Martelli M; Marasca R; Massaia M; Mauro FR; Minotti G; Molica S; Montillo M; Pinto A; Tedeschi A; Vitolo U; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):624-632. PubMed ID: 29512173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of adverse effects/toxicity of ibrutinib.
    Paydas S
    Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
    Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
    Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
    Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
    J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Toxicities Associated With Ibrutinib.
    Salem JE; Manouchehri A; Bretagne M; Lebrun-Vignes B; Groarke JD; Johnson DB; Yang T; Reddy NM; Funck-Brentano C; Brown JR; Roden DM; Moslehi JJ
    J Am Coll Cardiol; 2019 Oct; 74(13):1667-1678. PubMed ID: 31558250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ibrutinib-associated atrial fibrillation : A therapeutic challenge].
    Schmitt P; Demoulin R; Poyet R; Capilla E; Rohel G; Pons F; Jégo C; Sidibe S; Prevautel T; Druelle A; Brocq FX; Cellarier GR
    Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):321-324. PubMed ID: 36115721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
    Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
    Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib-related atrial fibrillation: A single center Australian experience.
    Ezad S; Khan AA; Cheema H; Ashraf A; Ngo DTM; Sverdlov AL; Collins NJ
    Asia Pac J Clin Oncol; 2019 Oct; 15(5):e187-e190. PubMed ID: 31250562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
    Shaikh H; Khattab A; Faisal MS; Chilkulwar A; Albrethsen M; Sadashiv S; Fazal S
    J Oncol Pharm Pract; 2019 Jul; 25(5):1265-1270. PubMed ID: 30045682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardio-Oncology: A Win-Win Situation: How Solving the Mystery of an Ibrutinib Off-Target Effect Reveals New Insights Into Atrial Fibrillation Mechanisms.
    Awan FT; Tong D; Zaha VG
    Circulation; 2020 Dec; 142(25):2456-2458. PubMed ID: 33347329
    [No Abstract]   [Full Text] [Related]  

  • 16. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Thorp BC; Badoux X
    Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
    Bernardeschi P; Pirrotta MT; Del Rosso A; Fontanelli G; Milandri C
    Eur J Haematol; 2019 Oct; 103(4):442-443. PubMed ID: 31287200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib-Associated Atrial Fibrillation.
    Ganatra S; Sharma A; Shah S; Chaudhry GM; Martin DT; Neilan TG; Mahmood SS; Barac A; Groarke JD; Hayek SS; Dani S; Venesy D; Patten R; Nohria A
    JACC Clin Electrophysiol; 2018 Dec; 4(12):1491-1500. PubMed ID: 30573111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders.
    Mulligan SP; Ward CM; Whalley D; Hilmer SN
    Br J Haematol; 2016 Nov; 175(3):359-364. PubMed ID: 27611114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.